Human microbiota aredistinctcommunities of microorganisms that resides at different body niches. Exploration of the human microbiome has become a reality due to the availability of powerful metagenomics and metatranscriptomic analysis technologies. Recent advances in sequencing and bioinformatics over the past decade help providea deep insight into the nature of the host-microbial interactions and identification of potential deriver genes and pathways associated with human health, well-being, and predisposition to different diseases.
Introduction
Humans are viewed as composites of human and microbial cells. Human microbiotaare complex and dynamic microbial communitiescomposed mainly ofbacteria, but also includes protozoa, archaea, viruses, and fungi that resides in and on different body niches such as oral cavity, throat, esophagus, stomach, colon, urogenital tract, respiratory tract, and skin . Metagenome and metatranscriptome refers to the study of collective genes and RNA derived from a specific microbiome respectively.
The term virome is used to describe the viral components (bacterial, archeal, eukaryotic virome, and virus-derived elements) while mycobiome refers to fungal organisms within human microbiota [5] [6] [7] [8] . As shown in figure (1), the human microbiome is composed of complex communities of viral (virome), bacterial (microbiota) and fungal (mycobiota) and their associated genetic material. The interplay among human microbiome and host cells affects human health and contribute in the pathogenesis of various diseases.
Marked differences in the abundance and diversity of microbiota are observed in healthy human individuals along with the presence of a strong niche specialization both within and among individuals 9 . These difference may be explained due to a number of factors including differences in host genetics, feeding habits, life style, and early life microbial exposure [10] [11] [12] . Moreover, changes in the composition of human microbiota have profound impacts on health and may predispose to different immunological and pathological conditions 9, 13, 14 . These microbial communities have a profound impact on human health and well-being, and each person's microbiome is thought to be unique. Differences in the microbiome composition can help explain why some people are more susceptible or resistant to certain diseases.
Exploration of the human microbiome has recently become possible due to the availability of powerful metagenomics and metatranscriptomic analysis protocols. Using these protocols, it become possible to have a better insight on the nature of the host-microbial interactions, and to identify potential deriver genes, and pathways associated with human health and diseases.
This review highlights the recent advances in human microbiome and explores possible uses of different microbial genetic signaturesin identifying possible disease risks. The exploration of novel therapeutic targets to improve human health, well-being, and to treat various diseases associated with microbiome dysbiosis are also mentioned.
Role of human microbiome in health
Accumulating evidence reveals that the gut microbiota plays a major role in promoting health, as a result of which it is often referred to as the ‛forgotten organ' 15 . The relationship between the host and microbiota is symbiotic and mutualistic, each deriving benefits from the other. These two terms are similar but mutualism is defined as ‛an interaction between species that is beneficial to both of them' and symbiosis as ‛the living together of two organisms in close association' 16 . While the host provides the microbiota with a protected and nutrient-rich environment, the microbiota enhance, e.g., digestion, immunity and neuronal development.
Microbiota are key to maintaining homeostasis where it confers many benefits for the host such as pathogen displacement, development of the immune system, vitamin production and absorption of nutrients
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. The influence of microbiota on health extends beyond the GI tract affecting almost every organ of the body 18, 19 . In the intestine, microbiota affect angiogenesis 20 and improve gut immunity and motility, as well as decreasing the permeability of the intestinal barrier. In distant organ such as the lungs, microbiota regulate immunological defense against viral infection 21 . Microbiota also influence behavior by reducing synaptic connectively and elevating anxiety 22, 19 and perception of pain 23 . In the liver, microbiota modulate hepatic metabolism in such a way as to decrease energy expenditure and promote adiposity 24 . In addition, absence of gut microbiota leads to more bone mass in association with fewer osteoclasts surface area of bone 25 . Recent studies also showed that microbiota are involved in the development of personalized medicine 26 , in xenobiotic metabolism 27 and in regulating bloodtissue barriers [28] [29] [30] .
Human microbiome and diseases (Dysbiosis)
Alterations in the composition of microbiota can result from exposure to various environmental factors such as diet, xenobiotics, drugs, and pathogens as shown in figure ( 2), which eventually contribute to the pathogenesis of various metabolic, neurological, immunological, and cancer promoting diseases. The collective microbiota of the gut whose DNA contributes to the metagenome have links with inflammatory bowel disease (IBD), liver disorders, ankylosing spondylitis, neurodegenerative diseases, obesity and associated noncommunicable diseases (NCDs) including diabetes mellitus, hypertension, atherosclerosis, coronary heart disease, and neurodegenerative diseases beside other condition [31] [32] [33] [34] [35] .
IntestinalDiseases
Due to the direct contact between the intestine and microbiota, it is predictable that alteration in the composition of microbiota could be involved in the pathogenesis of many intestinal disease such asCrohn's disease (CD) and ulcerative colitis (figure 3).
In CD, metagenomic analysis revealed a decrease in Firmicutes, in particular F. prausnitzii, and an increase in Enterobacteriaceae, especially the virulent invasive E. coli 36 . Alteration of gut microbiotamay affect mucosal health and immune system by acting on the epithelial barrier function, and regulation of the innate immune system 37 .Reduction in the number of F. prausnitzii is associated with an increasing risk for the recurrence of ileal CD 38 , another study confirmed an increase in the number of F. prausnitziiin pediatric CD 39 . Ott and colleagues demonstrated that CD was associated with altered fungal profile with a marked increase in the diversity of fungal community.In pediatric inflammatory bowel disease (IBD), dominance of Basidiomycotaspecies was recorded 40 .
Viruses associated with gut bacteria may affect the pathogenesis of CD and disease-specific viromes had been related to CD and ulcerative colitis (UC) 41 . Previous studies demonstrated a significant increase of Caudovirales bacteriophages concomitant with a reduction in the relative abundance of bacterial species, indicating a possible involvement of virome in bacterial dysbiosis associated with CD and UC 42 .
Alterations in the homeostasis of gut microbiota may induce low-grade intestinal inflammation associated with irritable bowel syndrome (IBS) 43, 44 . IBS was associated with an increase in the numbers of Ruminococcus, Clostridium, and Dorea, with a marked reduction in Bifidobacterium and Faecalibacterium spp. 45 . In comparison to normal population, an increase in the Firmicutes to Bacteroidetes ratio was evident in patients with IBS 46 . Dysbiosis of the gut microbiota is thought to play a crucial role in the development of mucosal lesions 47 and intestinal inflammation is generally believed to be associated with a specific reduction in the Bacteroidetes and
Firmicutes phyla specially reductions in the Clostridium leptum and Clostridium coccoides groups 48 . All of the aforementioned studies have certainly outlined a link between the gut microbiota and IBD.
Association between colorectal cancer (CRC) and the presence of specific causative organism has been suggested. For instance, the presence of high numbers of Fusobacterium in the gut microbiota has been linked to CRC 49, 50 . Interestingly, members of Fusobacterium has been associated with IBS 51 . The initiation of chronic inflammatory condition due to dysbiosis of gut microbiota lead to impairment of intestinal barrier, induction of inflammation through a host immune response, and in turn, increase in tumor growth 52 .
E. coli had been implicated in the initiation of CRC through polyketide synthase (pks) and mice mutants lacking the pks island had a decreased tumor growth and invasion compared to their wild-type pks+ counterparts 49 . Although there were strong correlations between inflammation induced by the presence of specific types of microorganisms and CRC, it was clear that further investigations were required to further explore the role of bacterial induced inflammation in tumorigenesis and CDC.
Gastric diseases
Although gastric pH, peristalsis and mucus layer play an essential protective role in preventing bacterial colonization in the stomach, maintenance of gastric microbiota homeostasis is essential for the stomach health. Five major phyla have been detected in the stomach including Modifications of gastric microbiota have been associated with gastric cancer or precancerous conditions. Although gastric cancer is known to be a multifactorial disease, H. pylori infection was found to actively contribute to its progression, probably by induction of chronic atrophic gastritis leading to reduction of gastric acid secretion and initiation of inflammatory cytokines 56, 57 .
The exact role of microbiota in the origination of gastric cancer is not clear and is poorly understood. Using culture-based protocol, a comparatively large number of anaerobic bacteria such as Clostridium and Bacteroides was identified in patients with gastric cancer. Elevation of the pH in in the gastric lumen due to reduction of acid-secreting cell number may influence colonization of microbiota within the gastric mucosa 58 . Subsequent studies have cast doubts on the existence of significant differences in gastric microbiota between control and gastric cancer patients, and that the microbiota in gastric cancer patients was dominated by different species of the genera Streptococcus, Lactobacillus, Veillonella, and Prevotella 57 .
Liver diseases
Disturbance tothe gut microbiota as a result of extrinsic factors such as unbalanced diet and alcohol consumption had been reported to contribute to nonalcoholic fatty liver disease There has been a reciprocal interplay between gut microbiota and liver, where alcohol-induced liver diseaseswere reported to impair intestinal barrier by increasing systemic levels of IL1b or tumor necrosis factor (TNFα), which disrupt tight junctions 73 . Increasing intestinal leakage might facilitates the movement of microbial products from the lumen of the gut into other distal organs including the liver 73 . In this respect, reduction of Gram-negative bacteria in the intestine due to the use of antibiotics has been associated with decrease in the levels of endotoxins and protection against liver disease after ethanol consumption 74 .
The dysbiosis of gut microbiota lead to increase in the level of endotoxin and production of ammonia which has been implicated in the development of hepatic encephalopathy associated with liver cirrhosis 75 . Interestingly, the number of bacterial species members of
Enterobacteriaceae including E. coli, Klebsiella, Proteus, and Enterobacter surge in the microbiota of patients with cirrhosis 67 .
Metabolic disorders
The gut microbiota plays important rolesin modulatinghost metabolism, extraction of energy from ingested food, and synthesis of various metabolites and vitamins.Gut microbiota are also essential in the modulation of lipid absorption and deposition, polysaccharide content and the production of short-chain fatty acids which have a marked impact on food intake, inflammatory tone, or insulin signaling. Recent findings suggested that an altered gut microbial composition was associated with metabolic diseases including obesity, diabetes, or non-alcoholic fatty liver disease (figure 3) 76 .
Changes to the gut microbiota play a critical role in the pathogenesis of obesity and diabetes. In humans it has been shown that gut microbiota composition differs between obese and lean subjects. Remarkably, inoculation of germ-free (GF) animals with gut microbiota derived from obese controls significantly increase the deposition of fat, and wasassociated with increase in the insulin resistance 77 . Leptin-deficient ob/ob obese mice displayed an alteration in the gut microbiota represented by a decrease in Bacteroidetes and a corresponding increase in
Firmicutes
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Recent metagenomics studies showed the presence of reduced numbers of butyrate-producing
Clostridiales and greater numbers of non-butyrate-producing ones in type 2 diabetes (T2DM), suggesting a protective role of butyrate-producing bacteria against T2DM 79, 80 . Furthermore, disruption of the gut barrier and microbiota-derived endotoxemia may contribute to the pathophysiology of T2DM and obesity. In this regard, modulation of the gut microbiota with antibiotics or prebiotics reduces the metabolic endotoximia, decreases inflammatory markers, enhances gut permeability, and alleviates glucose intolerance. Moreover, the microbiome signature may act as an early diagnostic marker for T2DM, and may provide a novel therapeutic target against T2DM and obesity [81] [82] [83] .
Lately, fecal microbiota transplantation (FMT) was reported to be highly successful therapeutic approach for the treatment of recurrent Clostridium difficile infection, a finding that might suggest a potential therapeutic protocol for metabolic syndrome 84 . Inoculation of fecal microbiota via gastroduodenal tube from lean donors into obese subjects resulted in an increase in the abundance (2.5 fold increase) and diversity of gut microbiota, improvement of insulin sensitivity, increase in the proportion of butyrate producer Roseburia intestinalis, and decrease in the level of short chain fatty acids 85 .
Dysbiotic gut microbiota has been found to play a role in obesity, other obesity related disorders such as type 2 diabetes (T2D), and metabolic syndrome [86] [87] [88] .The role ofmicrobiota to weight gain and host metabolism is not completely understood. It was suggested that in obese individual, the presence of specific microbial communities may increase the energy harvest and thus predispose to obesity 86, 88 .Other studies asserted that there can be several other mechanisms in which the microbial populations can influence weight gain and alteration of host metabolism 89 .
Neurodegenerative diseases
Aging is associated with progressive changes in the gastrointestinal motility, defective gut-blood Research has shown the possible role of microbiota in induction of different disease conditions and inexploringpossible noveltherapeutic and preventative strategies to improveand reversethe microbiome-associated diseases as well as promote global human health.
